{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:35:56Z","timestamp":1781850956398,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.semarthrit.2018.03.019","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T13:11:19Z","timestamp":1522847479000},"page":"686-693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Practical suggestions on intravenous iloprost in Raynaud\u2019s phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6727-1273","authenticated-orcid":false,"given":"Francesca","family":"Ingegnoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Schioppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Colaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Furst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Hunzelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0474-5344","authenticated-orcid":false,"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2018.03.019_bib1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0049-0172(75)90017-7","article-title":"Pathogenesis of systemic sclerosis: a vascular hypothesis","volume":"4","author":"Campbell","year":"1975","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/art.37988","article-title":"Review: evidence that systemic sclerosis is a vascular disease","volume":"65","author":"Matucci-Cerinic","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib5","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/14656566.8.5.607","article-title":"New therapeutic strategies in the management of systemic sclerosis","volume":"8","author":"Allanore","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5301\/jsrd.5000236","article-title":"Defining skin ulcers in systemic sclerosis: systematic literature review and proposed World Scleroderma Foundation (WSF) definition","volume":"2","author":"Suliman","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib8","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2017.05.024","article-title":"The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review","volume":"16","author":"Mostmans","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib9","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/rheumatology\/keq097","article-title":"Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions","volume":"49","author":"Amanzi","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/annrheumdis-2014-205897","article-title":"Digital ulcers predict a worse disease course in patients with systemic sclerosis","volume":"75","author":"Mihai","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 5","key":"10.1016\/j.semarthrit.2018.03.019_bib11","doi-asserted-by":"crossref","first-page":"v46","DOI":"10.1093\/rheumatology\/ken310","article-title":"Digital ulcers and outcomes assessment in scleroderma","volume":"47","author":"Matucci-Cerinic","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib12","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib13","unstructured":"Ingegnoli F. and Schioppo T. Effect of intravenous iloprost on systemic sclerosis-related peripheral vasculopathy: a systematic review and critical appraisal. PROSPERO CRD42017056460"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib14","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib15","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Br Med J"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib16","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib17","article-title":"The RAND\/UCLA appropriateness method user\u2019s manual","author":"Fitch","year":"2001","journal-title":"RAND"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib18","article-title":"Iloprost and cisaprost for Raynaud\u2019s phenomenon in progressive systemic sclerosis","author":"Pope","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib19","first-page":"209","article-title":"Iloprost treatment summer-suspension: effects on skin thermal properties and cytokine profile in systemic sclerosis patients","volume":"148","author":"Auriemma","year":"2013","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib20","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s10067-007-0613-2","article-title":"Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis","volume":"26","author":"Balbir-Gurman","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib21","first-page":"1830","article-title":"Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study","volume":"35","author":"Kawald","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib22","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kel038","article-title":"Iloprost treatment in patients with Raynaud\u2019s phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol","volume":"45","author":"Milio","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/bmj.298.6673.561","article-title":"Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud\u2019s phenomenon in patients with systemic sclerosis: a double blind randomised study","volume":"298","author":"Rademaker","year":"1989","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib24","first-page":"114","article-title":"Long-term effects of cyclic therapy with iloprost in systemic sclerosis","volume":"60","author":"Scarsi","year":"2008","journal-title":"Reumatismo"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib25","first-page":"503","article-title":"Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud\u2019s phenomenon. A randomized, controlled study","volume":"19","author":"Scorza","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib26","first-page":"1407","article-title":"Intravenous iloprost treatment of Raynaud\u2019s phenomenon and ischemic ulcers secondary to systemic sclerosis","volume":"19","author":"Wigley","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","article-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study","volume":"120","author":"Wigley","year":"1994","journal-title":"Ann Int Med"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib28","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2340\/0001555576236238","article-title":"Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis","volume":"76","author":"Zachariae","year":"1996","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib29","first-page":"745","article-title":"Iloprost as cyclic five-day infusions in the treatment of scleroderma. An open pilot study in 20 patients treated for one year","volume":"65","author":"Biasi","year":"1998","journal-title":"Rev Rhum Engl Ed"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10067-009-1155-6","article-title":"A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost","volume":"28","author":"Caramaschi","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/14397595.2016.1192761","article-title":"Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis","volume":"27","author":"Cestelli","year":"2017","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib32","first-page":"179","article-title":"Long term treatment of scleroderma-related digital ulcers with iloprost: a cohort study","volume":"35","author":"Colaci","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib33","doi-asserted-by":"crossref","first-page":"606","DOI":"10.7326\/0003-4819-114-7-606_1","article-title":"Iloprost for scleroderma","volume":"114","author":"Constans","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/0394632015606846","article-title":"Digital ulcers in scleroderma patients: a retrospective observational study","volume":"29","author":"De Cata","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.semarthrit.2018.03.019_bib35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00296-016-3582-4","article-title":"Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen","volume":"37","author":"Foti","year":"2017","journal-title":"Rheumatol Int"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218300131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218300131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:57:37Z","timestamp":1758733057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017218300131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0049017218300131"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.03.019","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical suggestions on intravenous iloprost in Raynaud\u2019s phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}